Allosteric Hemoglobin Modulators for Sickle Cell Oxygenation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders mediated by hemoglobin, such as sickle cell disease, lack effective therapeutics that can modulate hemoglobin's oxygen affinity and cellular oxygenation.
Innovation Solution
Development of specific compounds and pharmaceutical compositions that act as allosteric modulators of hemoglobin, specifically targeting hemoglobin S to increase oxygen affinity and treat related disorders like sickle cell anemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for sickle cell disease, then current standard therapy is provided, but effective modulation of hemoglobin oxygen affinity and cellular oxygenation is not achieved
Solution Approach 1:
The patent applies parameter changes by developing compounds that specifically alter the oxygen affinity parameter of hemoglobin S. The allosteric modulators bind to hemoglobin and change its conformational state, thereby modifying the P50 value (oxygen affinity parameter) to prevent sickling while maintaining adequate oxygen delivery to tissues.
Solution Approach 2:
The patent uses small molecule compounds as intermediaries that mediate between the pathological state of HbS polymerization and the desired physiological state. These compounds act as allosteric effectors that bind to hemoglobin and transmit conformational changes that prevent sickling without requiring genetic modification or direct intervention in the polymerization process.
2Object-affected harmful factors
If hemoglobin S polymerization is prevented, then sickle cell disease symptoms are treated, but oxygen affinity modulation and tissue oxygenation enhancement are not achieved
Solution Approach 1:
The patent applies local quality by creating compounds with specific molecular structures (such as the pyridine ring, aromatic ring, and heteroatom substitutions) that are optimized to bind to specific allosteric sites on hemoglobin. This localized molecular design enables selective modulation of hemoglobin properties without affecting other physiological systems, achieving both sickling prevention and oxygenation enhancement.
Solution Approach 2:
The patent employs composite molecular structures consisting of multiple functional groups (aromatic rings, heteroatoms, substituent groups) that work synergistically to achieve the dual effect of preventing HbS polymerization and enhancing oxygen affinity. The composite nature of these molecules allows simultaneous interaction with multiple hemoglobin binding sites to produce coordinated therapeutic effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively increase oxygen affinity of hemoglobin S, addressing oxygen deficiency in sickle cell anemia and potentially treating other conditions by enhancing tissue and cellular oxygenation.
Implementation Method 1
Development of specific compounds and pharmaceutical compositions that act as allosteric modulators of hemoglobin, specifically targeting hemoglobin S to increase oxygen affinity
Data Source
AI summary
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.